Tellus Therapeutics

company

About

Tellus Therapeutics develops novel small molecules derived from human maternal breast milk.

  • 1 - 10

Details

Last Funding Type
Series A
Last Funding Money Raised
$35M
Industries
Biotechnology
Founded date
Jan 1, 2018
Number Of Employee
1 - 10
Operating Status
Active

Tellus Therapeutics is developing novel small molecules derived from human maternal breast milk for the treatment of newborns with perinatal brain injury.

It was founded in 2018 and is based in Hillsborough, North Carolina.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$37M
Tellus Therapeutics has raised a total of $37M in funding over 2 rounds. Their latest funding was raised on Dec 13, 2022 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 13, 2022 Series A $35M 1 Xontogeny Detail
May 12, 2021 Seed $2M 1 Xontogeny Detail

Investors

Number of Lead Investors
Number of Investors
2
1
Tellus Therapeutics is funded by 1 investors. Xontogeny are the most recent investors.
Investor Name Lead Investor Funding Round
Xontogeny Yes Series A